Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Core Viewpoint - Jasper Therapeutics, Inc. is advancing its clinical-stage antibody therapy briquilimab, targeting mast cell-driven diseases, with a significant presentation scheduled at the 2025 AAD Annual Meeting [1][2] Company Overview - Jasper Therapeutics is focused on developing briquilimab as a treatment for chronic mast cell diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma [2] - Briquilimab is a targeted aglycosylated monoclonal antibody that inhibits the binding of stem cell factor to the c-Kit receptor, leading to mast cell depletion and reduced inflammation [2] Clinical Study Details - The upcoming presentation will showcase data from the Phase 1b/2a BEACON study, highlighting briquilimab's rapid and clinically meaningful reduction in disease activity in adults with CSU [2] - The presentation is scheduled for March 8, 2025, at 1 p.m. PST during the Late Breaking Research session at the AAD Annual Meeting [2]